SCOPUS 정보 검색 플랫폼

Diabetes Care

Volumn 27, Issue 9, 2004, Pages 2241-2242

Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol

(6) Normén, Lena a,b Frohlich, Jiri b,c Montaner, Julio c Harris, Marianne c Elliott, Tom b Bondy, Greg b,c

a Canadian HIV Trials Network (Canada)

b UNIVERSITY OF BRITISH COLUMBIA (Canada)

c ST PAUL S HOSPITAL (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARADOXICAL DRUG EFFECT;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HIV SEROPOSITIVITY; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PROCETOFEN; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 4444272941 PISSN: 01495992 EISSN: None Source Type: Journal
DOI: 10.2337/diacare.27.9.2241 Document Type: Article

Times cited : (29)

References (6)

1
- 0035140430
- Rosiglitazone monotherapy is effective in patients with type 2 diabetes
- Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86: 280-288, 2001
- (2001) J Clin Endocrinol Metab , vol.86 , pp. 280-288
- Lebovitz, H.E.¹ Dole, J.F.² Patwardhan, R.³ Rappaport, E.B.⁴ Freed, M.I.⁵

2
- 0032506273
- Mechanism of action of fibrates on lipid and lipoprotein metabolism
- Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093, 1998
- (1998) Circulation , vol.98 , pp. 2088-2093
- Staels, B.¹ Dallongeville, J.² Auwerx, J.³ Schoonjans, K.⁴ Leitersdorf, E.⁵ Fruchart, J.C.⁶

3
- 0031909536
- Clinical pharmacokinetics of fibric acid derivatives (fibrates)
- Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharrnacokinet 34:155-162, 1998
- (1998) Clin Pharrnacokinet , vol.34 , pp. 155-162
- Miller, D.B.¹ Spence, J.D.²

4
- 0032818309
- Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
- Baldwin SJ, Clarke SE, Chenery RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48: 424-432, 1999
- (1999) Br J Clin Pharmacol , vol.48 , pp. 424-432
- Baldwin, S.J.¹ Clarke, S.E.² Chenery, R.J.³

5
- 0035024343
- A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle
- Minnich A, Tian N, Byan L, Bilder G: A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280:E270-E279, 2001
- (2001) Am J Physiol Endocrinol Metab , vol.280
- Minnich, A.¹ Tian, N.² Byan, L.³ Bilder, G.⁴

6
- 0033305213
- Peroxisome proliferator-activated receptors: Nuclear control of metabolism
- Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688, 1999
- (1999) Endocr Rev , vol.20 , pp. 649-688
- Desvergne, B.¹ Wahli, W.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.